Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pharmasite Research Inc

Neither a doctor nor a teaching hospital

Research payments

$2,900,030

417 payments

Through program year 2025, Pharmasite Research Inc is reported as receiving $2,900,030 in research payments, across 417 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,055 36
2024 Research $110,197 20
2023 Research $428,974 46
2022 Research $375,918 48
2021 Research $350,979 64
2020 Research $790,066 90
2019 Research $839,842 113

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $601,413 93 payments
  2. AbbVie, Inc. $520,536 113 payments
  3. Janssen Research & Development, LLC $494,780 35 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $466,425 16 payments
  5. Eli Lilly and Company $426,015 44 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $98,381 47 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $95,204 1 payment
  8. Supernus Pharmaceuticals, Inc. $76,144 8 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $41,764 6 payments
  10. Biohaven Pharmaceuticals, Inc. $19,356 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $462,938 28 payments
  2. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $271,043 6 payments
  3. Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $189,855 16 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $159,799 3 payments
  5. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $109,868 12 payments
  6. A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder $107,750 12 payments
  7. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine $105,618 20 payments
  8. PoCC study in patients with PTSD $102,782 3 payments
  9. A Randomized, Double-Blind, Placebo-and Active-Controlled, Multicenter Study of Rapastinel as Monotherapy in Patients with Major Depressive Disorder $94,837 14 payments
  10. M16-837 $84,958 13 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $65,494 6 payments
  2. Other $9,951 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record